Advertisement

Migräne

  • Stefanie FörderreutherEmail author
  • Katharina Kamm
Living reference work entry
  • 24 Downloads
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Kopfschmerzen gehören zu den am häufigsten beklagten Symptomen überhaupt. Die Klassifikationskriterien der Internationalen Kopfschmerzgesellschaft (International Headache Society, IHS) definiert alle Kopfschmerzerkrankungen und bildet die Grundlage zur Einordnung von Kopfschmerzen. In der aktuell dritten Auflage der Internationalen Kopfschmerzklassifikation (ICHD-3) werden die bekannten primären und sekundären Kopfschmerzsyndrome beschrieben, kommentiert und in insgesamt 14 Kapitel eingeteilt. Die Kapitel 1–4 behandeln die primären Kopfschmerzformen wie Migräne, Spannungskopfschmerz, Clusterkopfschmerz, alle weiteren trigeminoautonomen Kopfschmerzen und andere seltene primäre Kopfschmerzerkrankungen, Kapitel 5–12 die sekundären Kopfschmerzen wie Subarachnoidalblutungen, intrazerebrale Blutungen oder die Riesenzellarteriitis, Kapitel 13 schmerzhafte Läsionen der Gehirnnerven und andere Gesichtsschmerzen und Kapitel 14 die nicht klassifizierbaren Formen. Trotz der großen Zahl möglicher Diagnosen kann man davon ausgehen, dass die Kenntnis der ca. 20–30 wichtigsten Kopfschmerzsyndrome und Differenzialdiagnosen ausreicht, um im klinischen Alltag über 95 % aller präsentierten Fälle einordnen zu können. Die gesamte Klassifikation mit allen Details kann auf der Webseite https://ichd-3.org/de/ abgerufen werden. Ausgewählte wichtige Kopfschmerzformen werden im Folgenden in der Reihenfolge der Kapitel der IHS-Klassifikation dargestellt. In diesem Kapitel wird die Migräne besprochen, weitere Kopfschmerzformen in Kap. „Spannungskopfschmerzen“, „Clusterkopfschmerzen und andere trigeminoautonome Kopfschmerzerkrankungen“, „Sonstige Kopfschmerzerkrankungen“ und „Sekundäre Kopfschmerzsyndrome“. Alle diagnostischen und therapeutischen Angaben entsprechen im Wesentlichen den Empfehlungen und Leitlinien der Deutschen Gesellschaft für Neurologie (DGN) und der Deutschen Migräne- und Kopfschmerzgesellschaft (DMKG) und können ausführlicher auf deren Webseiten nachgelesen werden.

Literatur

Zitierte Literatur

  1. Adams AM et al (2015) The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results. Cephalalgia 35(7):563–578PubMedPubMedCentralCrossRefGoogle Scholar
  2. Afridi SK et al (2013) A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 80(7):642–647PubMedCrossRefPubMedCentralGoogle Scholar
  3. Arkless K, Argunhan F, Brain SD (2019) CGRP discovery and timeline. Handb Exp Pharmacol 255:1–12Google Scholar
  4. Aurora SK, Brin MF (2017) Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache: J Head Face Pain 57(1):109–125CrossRefGoogle Scholar
  5. Baillie LE, Gabriele JM, Penzien DB (2014) A systematic review of behavioral headache interventions with an aerobic exercise component. Headache: J Head Face Pain 54(1):40–53CrossRefGoogle Scholar
  6. Cameron C et al (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache: J Head Face Pain 55:221–235CrossRefGoogle Scholar
  7. Charles A (2018) The migraine aura. Continuum: Lifelong learn Neurol 24(4):1009–1022PubMedPubMedCentralGoogle Scholar
  8. De Fusco M et al (2003) Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump α2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 33(2):192PubMedCrossRefPubMedCentralGoogle Scholar
  9. DeLange JM, Cutrer FM (2014) Our evolving understanding of migraine with aura. Curr Pain Headache Rep 18(10):453PubMedCrossRefPubMedCentralGoogle Scholar
  10. Detke HC et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211–e2221PubMedPubMedCentralCrossRefGoogle Scholar
  11. Dichgans M et al (2005) Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366(9483):371–377PubMedCrossRefGoogle Scholar
  12. Diener H-C et al (2012) Chronic migraine – classification, characteristics and treatment. Nat Rev Neurol 8(3):162PubMedCrossRefGoogle Scholar
  13. Diener H-C et al (2015) Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clin Med 15(4):344–350CrossRefGoogle Scholar
  14. Dodick DW (2018) A phase-by-phase review of migraine pathophysiology. Headache: J Head Face Pain 58:4–16CrossRefGoogle Scholar
  15. Dodick DW et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999–2008PubMedCrossRefGoogle Scholar
  16. Edvinsson L (2018) The CGRP pathway in migraine as a viable target for therapies. Headache: J Head Face Pain 58:33–47CrossRefGoogle Scholar
  17. Elbadawi A et al (2019) Meta-analysis of randomized trials on percutaneous patent foramen ovale closure for prevention of migraine. Acta Cardiol 74(2):124–129PubMedCrossRefGoogle Scholar
  18. Evans RW, Grosberg BM (2008) Expert opinion: retinal migraine: migraine associated with monocular visual symptoms (CME). Headache: J Head Face Pain 48(1):142–145CrossRefGoogle Scholar
  19. Gelfand AA (2018) Pediatric and adolescent headache. CONTINUUM: Lifelong Learn Neurol 24(4):1108–1136Google Scholar
  20. Giffin NJ et al (2016) The migraine postdrome: an electronic diary study. Neurology 87(3):309–313PubMedPubMedCentralCrossRefGoogle Scholar
  21. Goadsby PJ, Holland PR (2019) An update: pathophysiology of migraine. Neurol Clin 37(4):651–671PubMedCrossRefGoogle Scholar
  22. Goadsby PJ et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123–2132PubMedCrossRefGoogle Scholar
  23. Greene K, Irwin SL, Gelfand AA (2019) Pediatric migraine: an update. Neurol Clin 37(4):815–833PubMedCrossRefGoogle Scholar
  24. Hay DL, Walker CS (2017) CGRP and its receptors. Headache: J Head Face Pain 57(4):625–636CrossRefGoogle Scholar
  25. Karsan N, Prabhakar P, Goadsby P (2017) Premonitory symptoms of migraine in childhood and adolescence. Curr Pain Headache Rep 21(7):34PubMedPubMedCentralCrossRefGoogle Scholar
  26. Kropp P et al (2016) Entspannungsverfahren und verhaltenstherapeutische Interventionen zur Behandlung der Migräne. Nervenheilkunde 35(07/08):502–515CrossRefGoogle Scholar
  27. Lampl C et al (2005) Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 76(12):1730–1732PubMedPubMedCentralCrossRefGoogle Scholar
  28. Lampl C et al (2015) Neck pain in episodic migraine: premonitory symptom or part of the attack? J Headache pain 16(1):80PubMedCentralCrossRefPubMedGoogle Scholar
  29. Laurell K, Lundström E (2012) Migrainous infarction: aspects on risk factors and therapy. Curr Pain Headache Rep 16(3):255–260PubMedCrossRefGoogle Scholar
  30. Linde K et al (2016) Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev (6):CD001218.  https://doi.org/10.1002/14651858.CD001218.pub3
  31. MaassenVanDenBrink A et al (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37(9):779–788PubMedCrossRefGoogle Scholar
  32. May A, Burstein R (2019) Hypothalamic regulation of headache and migraine. Cephalalgia 39(13):1710–1719PubMedCrossRefGoogle Scholar
  33. Olesen J (2018) Headache classification committee of the International Headache Society (IHS) The international classification of headache disorders, asbtracts. Cephalalgia 38(1):1–211CrossRefGoogle Scholar
  34. Ong JJY, Wei DY, Goadsby PJ (2018) Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs 78:411–437.  https://doi.org/10.1007/s40265-018-0865-yCrossRefPubMedGoogle Scholar
  35. Ophoff RA et al (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87(3):543–552PubMedCrossRefGoogle Scholar
  36. Puledda F, Messina R, Goadsby PJ (2017) An update on migraine: current understanding and future directions. J Neurol 264(9):2031–2039PubMedPubMedCentralCrossRefGoogle Scholar
  37. Russell MB, Ducros A (2011) Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 10(5):457–470PubMedCrossRefGoogle Scholar
  38. Schwedt TJ (2014) Chronic migraine. BMJ 348:g1416PubMedCrossRefGoogle Scholar
  39. Shah DR, Dilwali S, Friedman DI (2018) Current aura without headache. Curr Pain Headache Rep 22(11):77PubMedCrossRefPubMedCentralGoogle Scholar
  40. Silberstein SD et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122PubMedCrossRefGoogle Scholar
  41. Skljarevski V et al (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442–1454PubMedCrossRefGoogle Scholar
  42. Stauffer VL et al (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA neurology 75(9):1080–1088PubMedPubMedCentralCrossRefGoogle Scholar
  43. Stovner LJ, Andree C (2010) Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 11(4):289PubMedPubMedCentralCrossRefGoogle Scholar
  44. Tepper S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434PubMedCrossRefGoogle Scholar
  45. Thissen S et al (2014) Persistent migraine aura: new cases, a literature review, and ideas about pathophysiology. Headache: J Head Face Pain 54(8):1290–1309CrossRefGoogle Scholar
  46. Thorlund K et al (2017) Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia 37(10):965–978PubMedCrossRefGoogle Scholar
  47. Viana M et al (2017) Clinical features of migraine aura: results from a prospective diary-aided study. Cephalalgia 37(10):979–989PubMedCrossRefGoogle Scholar
  48. Vongvaivanich K et al (2015) Late-life migraine accompaniments: a narrative review. Cephalalgia 35(10):894–911PubMedCrossRefGoogle Scholar

Weiterführende Literatur

  1. Abu-Arafeh I et al (2010) Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol 52(12):1088–1097CrossRefGoogle Scholar
  2. Akerman S, Holland PR, Goadsby PJ (2011) Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 12(10):570PubMedCrossRefGoogle Scholar
  3. Barbanti P, Aurilia C, Dall’Armi V, Egeo G, Fofi L, Bonassi S (2016) The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients. Cephalalgia 36:1334–1340PubMedCrossRefGoogle Scholar
  4. Burch R (2020) Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review. Headache: J Head Face Pain 60(1):200–216CrossRefGoogle Scholar
  5. Calhoun AH et al (2010) The prevalence of neck pain in migraine. Headache: J Head Face Pain 50(8):1273–1277CrossRefGoogle Scholar
  6. Charles A (2018) The pathophysiology of migraine: implications for clinical management. Lancet Neurology 17(2):174–182PubMedCrossRefGoogle Scholar
  7. Charles A (2018) The migraine aura. Continuum: Lifelong learn Neurol 24(4):1009–1022Google Scholar
  8. Charlesworth BR et al (2003) Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine. Cns Drugs 17(9):653–667PubMedCrossRefGoogle Scholar
  9. Cortelli P et al (2011) Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol Sci 32(1):95–98CrossRefGoogle Scholar
  10. DeLange JM, Cutrer FM (2014) Our evolving understanding of migraine with aura. Curr Pain Headache Rep 18(10):453Google Scholar
  11. Derry CJ, Derry S, Moore RA (2012a) Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev (2):CD009663.  https://doi.org/10.1002/14651858.CD009663
  12. Derry CJ, Derry S, Moore RA (2012b) Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev (2):CD009665.  https://doi.org/10.1002/14651858.CD009665
  13. Derry CJ, Derry S, Moore RA (2012c) Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev (2):CD008615.  https://doi.org/10.1002/14651858.CD008615.pub2
  14. Derry CJ, Derry S, Moore RA (2014) Sumatriptan (all routes of administration) for acute migraine attacks in adults-overview of Cochrane reviews. Cochrane Database Syst Rev 5Google Scholar
  15. Dodick D et al (2005) Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine. CNS drugs 19(2):125–136PubMedCrossRefGoogle Scholar
  16. Ernst E (1999) Homeopathic prophylaxis of headaches and migraine? A systematic review. J Pain Symptom Manag 18(5):353–357CrossRefGoogle Scholar
  17. Evans R, Aurora S (2012) Migraine with persistent visual aura. Headache 52(3):494–501PubMedCrossRefGoogle Scholar
  18. Gawel M et al (2005) Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine – results from phase 1 of the REALIZE Study. Headache: J Head Face Pain 45(1):7–16CrossRefGoogle Scholar
  19. Giffin N et al (2003) Premonitory symptoms in migraine: an electronic diary study. Neurology 60(6):935–940PubMedCrossRefGoogle Scholar
  20. Goadsby PJ, Holland PR (2019) An update: pathophysiology of migraine. Neurol Clin 37(4):651–671PubMedCrossRefGoogle Scholar
  21. Hansen JM, Goadsby PJ, Charles AC (2016) Variability of clinical features in attacks of migraine with aura. Cephalalgia 36(3):216–224PubMedCrossRefGoogle Scholar
  22. Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6(10):573PubMedCrossRefGoogle Scholar
  23. Holroyd KA et al (2010) Effect of preventive (β blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 341:c4871PubMedPubMedCentralCrossRefGoogle Scholar
  24. Kirchmann M, Thomsen LL, Olesen J (2006) Basilar-type migraine: clinical, epidemiologic, and genetic features. Neurology 66(6):880–886PubMedCrossRefGoogle Scholar
  25. Koseoglu E et al (2015) The role of exercise in migraine treatment. J Sports Med Phys Fit 55(9):1029–1036Google Scholar
  26. Kowacs PA, Utiumi MA, Piovesan EJ (2015) The visual system in migraine: from the bench side to the office. Headache: J Head Face Pain 55:84–98CrossRefGoogle Scholar
  27. Kropp P et al (2017) Entspannungsverfahren und verhaltenstherapeutische Interventionen zur Behandlung der Migräne. Schmerz 31(5):433–447PubMedCrossRefGoogle Scholar
  28. Kruit MC et al (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291(4):427–434PubMedCrossRefGoogle Scholar
  29. Kruit MC et al (2005) Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 128(9):2068–2077PubMedCrossRefGoogle Scholar
  30. Laurell K et al (2011) Migrainous infarction: a Nordic multicenter study. Eur J Neurol 18(10):1220–1226PubMedCrossRefGoogle Scholar
  31. Leao AA (1944) Spreading depression of activity in the cerebral cortex. J Neurophysiol 7(6):359–390CrossRefGoogle Scholar
  32. Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR (2009) Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev (1):CD001218.  https://doi.org/10.1002/14651858.CD001218.pub2
  33. Mattle HP et al (2015) Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J 37(26):2029–2036CrossRefGoogle Scholar
  34. Messlinger K, Fischer MJ, Lennerz JK (2011) Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. Keio J Med 60(3):82–89PubMedCrossRefGoogle Scholar
  35. Miglis MG (2018) Migraine and autonomic dysfunction: which is the horse and which is the jockey? Curr Pain Headache Rep 22(3):19PubMedCrossRefGoogle Scholar
  36. Nestoriuc Y et al (2008) Biofeedback treatment for headache disorders: a comprehensive efficacy review. Appl Psychophysiol Biofeedback 33(3):125–140PubMedCrossRefGoogle Scholar
  37. Ong JJY, Wei DY-T, Goadsby PJ (2018) Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs 1–27Google Scholar
  38. Oskoui M et al (2019) Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 93(11):487–499PubMedCrossRefGoogle Scholar
  39. Overath CH et al (2014) Does an aerobic endurance programme have an influence on information processing in migraineurs? J Headache Pain 15(1):11PubMedPubMedCentralCrossRefGoogle Scholar
  40. Patniyot IR, Gelfand AA (2016) Acute treatment therapies for pediatric migraine: a qualitative systematic review. Headache: J Head Face Pain 56(1):49–70CrossRefGoogle Scholar
  41. Plato BM (2016) Rare complications of migraine with aura. Headache: J Head Face Pain 56(8):1373–1379CrossRefGoogle Scholar
  42. Pradhan S, Chung SM (2004) Retinal, ophthalmic, or ocular migraine. Current Neurol Neurosci Rep 4(5):391–397CrossRefGoogle Scholar
  43. Reilinger T (2014) Genetik primärer Kopfschmerzen. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 57(8):919–927CrossRefGoogle Scholar
  44. Rozen TD (2015) Emergency department and inpatient management of status migrainosus and intractable headache. Continuum: Lifelong Learn Neurol 21(4):1004–1017Google Scholar
  45. Schulte LH, Jürgens TP, May A (2015) Photo-, osmo-and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers? J Headache Pain 16(1):14PubMedPubMedCentralCrossRefGoogle Scholar
  46. Silberstein SD (1995) Migraine symptoms: results of a survey of self-reported migraineurs. Headache: J Head Face Pain 35(7):387–396CrossRefGoogle Scholar
  47. Straube A, Andreou A (2019) Primary headaches during lifespan. J Headache Pain 20(1):35PubMedPubMedCentralCrossRefGoogle Scholar
  48. Terrin A et al (2018) When migraine mimics stroke: a systematic review. Cephalalgia 38(14):2068–2078PubMedCrossRefGoogle Scholar
  49. Tfelt-Hansen PC (2011) Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register. J Headache Pain 12(4):399PubMedPubMedCentralCrossRefGoogle Scholar
  50. Thorlund K et al (2014) Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia 34(4):258–267PubMedCrossRefGoogle Scholar
  51. Vécsei L et al (2018) Treating status migrainosus in the emergency setting: what is the best strategy? Expert Opin Pharmacother 19(14):1523–1531PubMedCrossRefGoogle Scholar
  52. Vgontzas A, Burch R (2018) Episodic migraine with and without aura: key differences and implications for pathophysiology, management, and assessing risks. Curr Pain Headache Rep 22(12):78PubMedCrossRefGoogle Scholar
  53. Walach H et al (1997) Classical homeopathic treatment of chronic headaches. Cephalalgia 17(2):119–126PubMedCrossRefGoogle Scholar
  54. Walach H et al (2000) The long-term effects of homeopathic treatment of chronic headaches: 1 year follow up. Cephalalgia 20(9):835–837PubMedCrossRefGoogle Scholar
  55. Wallasch T-M, Kropp P (2012) Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study. J Headache Pain 13(7):521PubMedPubMedCentralCrossRefGoogle Scholar
  56. Wallasch TM, Angeli A, Kropp P (2012) Outcomes of a headache-specific cross-sectional multidisciplinary treatment program. Headache: J Head Face Pain 52(7):1094–1105CrossRefGoogle Scholar
  57. Whitmarsh T, Coleston-Shields D, Steiner T (1997) Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. Cephalalgia 17(5):600–604PubMedCrossRefGoogle Scholar
  58. Xu H et al (2016) Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain 17(1):113PubMedPubMedCentralCrossRefGoogle Scholar
  59. Yoon M et al (2012) Prevalence of primary headaches in Germany: results of the German Headache Consortium Study. J Headache Pain 13(3):215PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2020

Authors and Affiliations

  1. 1.Neurologischer KonsiliardienstNeurologische Klinik und Poliklinik der LMU MünchenMünchenDeutschland
  2. 2.Neurologische Klinik und Poliklinik der LMUGroßhadernMünchenDeutschland

Personalised recommendations